Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.
暂无分享，去创建一个
T. Choueiri | M. Atkins | A. Ribas | F. Hodi | D. McDermott | John A Thompson | S. Ebbinghaus | R. Perini | W. Hwu | A. Tosolini | C. Gause | M. Brookes | J. Thompson | Zijiang Yang